Effects of metformin and pioglitazone in polycystic ovarian syndrome
Not Applicable
- Conditions
- Polycystic ovarian syndrome.Endocrine nutritional and metabolic diseases
- Registration Number
- IRCT201008094179N3
- Lead Sponsor
- Vice-chancellor for research, Kermanshah University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 56
Inclusion Criteria
High TSH with FT4 in normal range
Exclusion criteria: receiving Levothyroxine, glucocorticoids, aspirin, amiodaron, lipid lowering agents, OCP, dopamine antagonist eg. metoclopramide and domperidone in recent 6 months, diabetic patients, pregnant women, women in menopause ages, patients older than 60 years
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood pressure. Timepoint: 3 months. Method of measurement: Barometers.;Fasting sugar serum level. Timepoint: 3 months. Method of measurement: mg/dl.;Fasting Insulin serum level. Timepoint: 3 months. Method of measurement: Uiu/ml.;Testostrone serum level. Timepoint: 3 months. Method of measurement: ngr/dl.;DHEADS serum level. Timepoint: 3 months. Method of measurement: ngr/dl.
- Secondary Outcome Measures
Name Time Method Cholesterol serum level. Timepoint: 3 months. Method of measurement: mg/dl.;Triglyceride serum level. Timepoint: 3 months. Method of measurement: mg/dl.;LDL serum level. Timepoint: 3 months. Method of measurement: mg/dl.;HDL serum level. Timepoint: 3 months. Method of measurement: mg/dl.